Massimiliano Lorenzini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3272605/publications.pdf

Version: 2024-02-01

50 papers	2,892 citations	236612 25 h-index	214527 47 g-index
50 all docs	50 docs citations	50 times ranked	3400 citing authors

#	Article	IF	Citations
1	Transthyretin-related amyloidoses and the heart: a clinical overview. Nature Reviews Cardiology, 2010, 7, 398-408.	6.1	286
2	Role of 99mTc-DPD Scintigraphy in Diagnosis and Prognosis of Hereditary Transthyretin-Related Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2011, 4, 659-670.	2.3	264
3	Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. European Heart Journal, 2017, 38, 1895-1904.	1.0	258
4	Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal, 2013, 34, 520-528.	1.0	252
5	Cardiac amyloidosis: the great pretender. Heart Failure Reviews, 2015, 20, 117-124.	1.7	147
6	Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 147-155.	1.4	115
7	Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 142-150.	1.4	106
8	Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. European Journal of Heart Failure, 2020, 22, 507-515.	2.9	106
9	Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2016, 9, .	1.6	103
10	Prognostic Implications of the Doppler Restrictive Filling Pattern in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2009, 104, 1727-1731.	0.7	93
11	Identification ofÂTTR-Related Subclinical Amyloidosis WithÂ99mTc-DPD Scintigraphy. JACC: Cardiovascular Imaging, 2014, 7, 531-532.	2.3	91
12	Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2016, 9, 325-327.	2.3	89
13	Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. Journal of the American College of Cardiology, 2020, 76, 550-559.	1.2	89
14	Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1617-1623.	3.3	79
15	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circulation: Heart Failure, 2020, 13, e006832.	1.6	75
16	Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and metaâ€analysis. ESC Heart Failure, 2019, 6, 1041-1051.	1.4	73
17	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiology, 2020, 5, 73.	3.0	69
18	Significance of Magnetic Resonance Imaging in Apical Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2010, 105, 1592-1596.	0.7	59

#	Article	IF	Citations
19	Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3063-3073.	1.0	51
20	Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 118, 432-439.	0.7	45
21	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	1.2	45
22	Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure. European Journal of Heart Failure, 2018, 20, 1417-1425.	2.9	36
23	Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure. JAMA Cardiology, 2021, 6, 891.	3.0	36
24	Defining the Diagnosis in Echocardiographically Suspected Senile Systemic Amyloidosis. JACC: Cardiovascular Imaging, 2012, 5, 755-758.	2.3	33
25	Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT?. Journal of Nuclear Cardiology, 2017, 24, 746-749.	1.4	31
26	Troponin T elevation in acute aortic syndromes: Frequency and impact on diagnostic delay and misdiagnosis. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 61-71.	0.4	26
27	Cardiac involvement in hereditary-transthyretin related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 16-21.	1.4	24
28	Diagnostic performance of standard electrocardiogram for prediction of infarct related artery and site of coronary occlusion in unselected STEMI patients undergoing primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 326-339.	0.4	22
29	Redefining the histopathologic profile of acute aortic syndromes: Clinical and prognostic implications. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1776-1785.e6.	0.4	22
30	The complex interplay among atherosclerosis, inflammation, and degeneration in ascending thoracic aortic aneurysms. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 1434-1443.e6.	0.4	20
31	ESC EORP Cardiomyopathy Registry: realâ€life practice of genetic counselling and testing in adult cardiomyopathy patients. ESC Heart Failure, 2020, 7, 3013-3021.	1.4	19
32	Nuclear imaging for cardiac amyloidosis. Heart Failure Reviews, 2015, 20, 145-154.	1.7	15
33	Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis. BMJ Open, 2012, 2, e001267.	0.8	13
34	Long-term prognostic role of cerebrovascular disease and peripheral arterial disease across the spectrum of acute coronary syndromes. Atherosclerosis, 2016, 245, 43-49.	0.4	13
35	Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset. Orphanet Journal of Rare Diseases, 2019, 14, 263.	1.2	12
36	Long-Term Outcomes and Causes of Death After Acute Coronary Syndrome in Patients in the Bologna, Italy, Area. American Journal of Cardiology, 2015, 115, 171-177.	0.7	11

#	Article	IF	Citations
37	Isolated aortic root dilation in homocystinuria. Journal of Inherited Metabolic Disease, 2018, 41, 109-115.	1.7	11
38	Long-term Follow up of Patients with Acute Aortic Syndromes: Relevance of both Aortic and Non-aortic Events. European Journal of Vascular and Endovascular Surgery, 2018, 56, 200-208.	0.8	10
39	Prevalence of TTR variants detected by whole-exome sequencing in hypertrophic cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 243-247.	1.4	10
40	Acute heart failure in patients with acute aortic syndrome: pathophysiology and clinicalâ€“prognostic implications. European Journal of Heart Failure, 2015, 17, 917-924.	2.9	9
41	Etiology of Amyloidosis Determines Myocardial 99mTc-DPD Uptake in Amyloidotic Cardiomyopathy. Clinical Nuclear Medicine, 2015, 40, 446-447.	0.7	6
42	What is the acceptable rate of false positives for STEMI within a primary PCI network? Insights from a metropolitan system with direct ambulance-based access. International Journal of Cardiology, 2012, 154, 356-358.	0.8	5
43	The complex interplay between systolic and diastolic function at rest and during exercise in heart failure: the case of cardiac amyloidosis. European Journal of Heart Failure, 2017, 19, 1466-1467.	2.9	4
44	The complex interplay between fitness, genetics, lifestyle, and inflammation in the pathogenesis of coronary atherosclerosis: lessons from the Amazon rainforest. European Heart Journal Supplements, 2019, 21, B76-B79.	0.0	3
45	Tafamidis for the treatment of transthyretin amyloidosis. Future Cardiology, 2019, 15, 53-61.	0.5	3
46	Broadening the Phenotypic Spectrum andÂthe Diagnostic Needs of TTR-Related Cardiac Amyloidosis â^—. Journal of the American College of Cardiology, 2017, 70, 478-480.	1.2	2
47	An unusual case of a congenital aorto-left atrial tunnel. Cardiovascular Pathology, 2014, 23, 241-243.	0.7	1
48	The Authors Reply:. JACC: Cardiovascular Imaging, 2016, 9, 906.	2.3	0
49	Extracardiac imaging in amyloidosis: A long and winding (but possible) road. International Journal of Cardiology, 2018, 254, 351-352.	0.8	0
50	Cardiac magnetic resonance assessment of progressive myo-pericarditis due to cobalt cardiotoxicity. European Heart Journal Cardiovascular Imaging, 2021, 22, e71-e71.	0.5	0